Materials and Resources
- Nulojix Distribution Program
- Dosing and Administration Guide
- Product Fact Sheet
- Dosing and Administration Video
- MOA Video
- ENLiST Registry
This site is intended for
US Healthcare Professionals only.
Management of Immunosuppression
Progressive Multifocal Leukoencephalopathy (PML)
Other Malignancies and Serious Infections
Liver Transplant: use in liver transplant patients is not recommended due to increased risk of graft loss and death in a clinical trial with more frequent administration of NULOJIX than studied in kidney transplant, along with MMF and corticosteroids
Immunizations: avoid use of live vaccines during NULOJIX treatment
Coadministration with Anti-Thymocyte Globulin: in de novo kidney transplant recipients, especially those with other predisposing risk factors for venous thrombosis of the renal allograft, coadministration (at the same or nearly the same time) with anti-thymocyte globulin may pose a risk for venous thrombosis of the renal allograft. If anti-thymocyte globulin (or any other cell-depleting induction treatment) and NULOJIX will be administered concomitantly, a 12-hour interval between the two administrations is suggested
Acute Rejection and Graft Loss with Corticosteroid Minimization
Pregnancy Category C: based on animal data, NULOJIX may cause fetal harm. NULOJIX should not be used in pregnancy unless potential benefit to the mother outweighs potential risk to the fetus. To monitor maternal-fetal outcomes of pregnant women who have received NULOJIX, or whose partners have received NULOJIX, healthcare providers are strongly encouraged to register pregnant patients in the
National Transplant Pregnancy Registry (NTPR) by calling 1-877-955-6877 1-877-955-6877
Post-Transplant Lymphoproliferative Disorder (PTLD)
Management of Immunosuppression
Progressive Multifocal Leukoencephalopathy (PML)
Other Malignancies and Serious Infections
Liver Transplant: use in liver transplant patients is not recommended due to increased risk of graft loss and death in a clinical trial with more frequent administration of NULOJIX than studied in kidney transplant, along with MMF and corticosteroids
Acute Rejection and Graft Loss with Corticosteroid Minimization
Immunizations: avoid use of live vaccines during NULOJIX treatment
Coadministration with Anti-Thymocyte Globulin: in de novo kidney transplant recipients, especially those with other predisposing risk factors for venous thrombosis of the renal allograft, coadministration (at the same or nearly the same time) with anti-thymocyte globulin may pose a risk for venous thrombosis of the renal allograft. If anti-thymocyte globulin (or any other cell-depleting induction treatment) and NULOJIX will be administered concomitantly, a 12-hour interval between the two administrations is suggested
Pregnancy Category C: based on animal data, NULOJIX may cause fetal harm. NULOJIX should not be used in pregnancy unless potential benefit to the mother outweighs potential risk to the fetus. To monitor maternal-fetal outcomes of pregnant women who have received NULOJIX, or whose partners have received NULOJIX, healthcare providers are strongly encouraged to register pregnant patients in the
National Transplant Pregnancy Registry (NTPR) by calling 1-877-955-6877 1-877-955-6877
Nursing Mothers: discontinue NULOJIX or nursing, considering importance of NULOJIX to the mother
Most Common Adverse Reactions (≥20%): anemia (45%), diarrhea (39%), urinary tract infection (37%), peripheral edema (34%), constipation (33%), hypertension (32%), pyrexia (28%), graft dysfunction (25%), cough (24%), nausea (24%), vomiting (22%), headache (21%), hypokalemia (21%), hyperkalemia (20%), and leukopenia (20%)
Please see Full Prescribing Information, including Boxed WARNINGS.
This information is intended for US Health Care Professionals.
I am a US Health Care Professional.
I am not a US Health Care Professional.
Continue to Consumer Website
This Internet site may provide links or references to other sites. Bristol-Myers Squibb has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this Internet site.
Would you like to leave this site?